Tag: omics-based clinical trials market trends

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Omics-Based Clinical Trials Market Growth From $34.48 Billion In 2026 To $47.77 Billion By 2030 At A CAGR Of 8.5%

The market for omics-based clinical trials has experienced significant expansion recently. Projections indicate a rise from $31.71 billion in 2025 to $34.49 billion in 2026, reflecting a compound annual growth rate of 8.8%. Factors fueling this historical growth include the escalating intricacy of clinical trial methodologies, advancements in genomic and proteomic investigations, a mounting need for tailored medical treatments, the broadening of clinical research facilities, and enhanced partnerships between pharmaceutical companies and academic bodies.

The omics-based clinical trials market demonstrates a trajectory of robust expansion, projected to reach a valuation of $47.78 billion by 2030. This impressive growth is underpinned by a compound annual growth rate of 8.5% over the forecast period, fueled by several key drivers. These include the escalating embrace of personalized medicine strategies, a surge in financial commitment towards data-centric clinical trial methodologies, the broadened application of AI-powered patient recruitment solutions, increasing validation of omics-derived endpoints by regulatory bodies, and a heightened need for optimizing clinical trial results. Furthermore, significant developments anticipated within this timeframe encompass a greater reliance on biomarker-guided trial frameworks, more extensive utilization of multi-omics data for patient segmentation, the deeper incorporation of real-world evidence analysis, a widened scope for precision oncology trials, and a more pronounced concentration on optimizing trials through data-focused approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp

Omics-Based Clinical Trials Market Demand Drivers Creating New Revenue Opportunities

The burgeoning field of personalized medicine is set to significantly fuel the expansion of the omics-based clinical trials sector. This approach to healthcare customizes disease prevention, diagnosis, and treatment based on a patient’s unique biological makeup. Such a shift towards individualized care is largely driven by advancements in genomic technologies, which now facilitate rapid and affordable examination of genetic information, paving the way for precisely targeted therapies. Omics-based clinical trials are instrumental in realizing personalized medicine’s potential by facilitating the detailed profiling of an individual’s genes, proteins, and metabolic pathways, thereby enabling the development of highly effective and patient-specific treatment plans. Illustrating this trend, the Personalized Medicine Coalition reported that in 2023, the US Food and Drug Administration authorized 16 novel personalized treatments for individuals with rare diseases, a notable increase from the six such approvals granted in 2022; these 2023 authorizations also included seven cancer therapies and three treatments for other conditions. Consequently, the growing need for personalized medicine directly stimulates the growth trajectory of the omics-based clinical trials market.

Omics-Based Clinical Trials Market Segment Analysis And Revenue Opportunities

The omics-based clinical trials market covered in this report is segmented –

1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics

2) By Phase: Phase I, Phase II, Phase III, Phase IV

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders

5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories

Subsegments:

1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing

2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping

3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis

4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

Omics-Based Clinical Trials Market Trends Driving Strategic Industry Expansion

Businesses leading the charge in the omics-driven clinical trials sector are prioritizing novel approaches, including the adoption of HiFi sequencing technology, with the goal of boosting the precision, rapidity, and comprehensiveness of multi-omics data interpretation, thereby refining clinical trial results and tailoring therapeutic interventions. HiFi sequencing represents a sophisticated next-generation sequencing (NGS) methodology that generates extensive, exceptionally accurate readings through circular consensus sequencing (CCS), thereby facilitating a thorough and exact examination of genomic, transcriptomic, and epigenomic data. As a prime example, in October 2024, Pacific Biosciences of California Inc., an American biotech firm, partnered with Singapore’s Agency for Science, Technology, and Research (A*STAR) and South Korea’s Macrogen Inc. to inaugurate a premier laboratory in Singapore, leveraging advanced long-read sequencing capabilities to expedite genomic advancements. This facility empowers researchers to undertake sophisticated genomic investigations with enhanced accuracy and efficiency, catering to diverse applications such as whole genome sequencing, transcriptomics, epigenetics, and metagenomics, while also cultivating international and local scientific partnerships to speed up breakthroughs in personalized medicine, rare disease identification, and precision oncology, complemented by training initiatives and shared access to high-capacity sequencing resources to build expertise and foster innovation across the Asia-Pacific region.

Omics-Based Clinical Trials Market Leading Players Shaping Industry Direction

Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.

Access The Complete Omics-Based Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

Omics-Based Clinical Trials Market Regional Analysis: Which Region Leads By Revenue?

North Americawas the largest region in the omics-based clinical trials market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Expansion Is Expected For The Omics-Based Clinical Trials Market Over The Forecast Period?

The omics-based clinical trials market size has experienced robust growth recently. This market is projected to expand from $31.71 billion in 2025 to $34.49 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 8.8%. Historically, this expansion has been driven by factors such as the increasing intricacy of clinical trial designs, the surge in genomic and proteomic research, a growing need for personalized therapies, the broadening of clinical research infrastructure, and enhanced partnerships between pharmaceutical companies and academic bodies.

The omics-based clinical trials market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $47.78 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. Key factors driving this growth during the forecast period include the escalating adoption of precision medicine approaches, a surge in investments towards data-driven clinical trials, the broadened use of AI for patient recruitment, increasing regulatory approval for omics-based endpoints, and a heightened need for effective trial outcomes. Significant trends observed in the forecast period encompass the wider embrace of biomarker-driven trial designs, an increase in the application of multi-omics for patient stratification, the expanding incorporation of real-world evidence analytics, the growth of precision oncology clinical trials, and an intensified concentration on data-centric approaches for trial optimization.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp

What Primary Factors Are Fueling The Expansion Of The Omics-Based Clinical Trials Market?

The escalating need for personalized medicine is projected to drive the expansion of the omics-based clinical trials market in the coming years. Personalized medicine describes a medical strategy that customizes disease prevention, diagnosis, and treatment according to the distinct characteristics of each individual patient. The increasing demand for personalized medicine stems from advancements in genomic technologies, which facilitate quicker, more economical analysis of individual genetic profiles to guide specific treatments. Omics-based clinical trials bolster personalized medicine by enabling the identification of individual genetic, proteomic, and metabolic profiles, thereby allowing for more targeted and effective treatment strategies precisely tailored for each patient. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023. This figure represents an increase from six approvals in 2022, with the 2023 approvals further comprising seven oncology therapies and three treatments addressing various other conditions. Consequently, the rising demand for personalized medicine is a significant impetus behind the growth of the omics-based clinical trials market.

How Is The Omics-Based Clinical Trials Market Structured Across Different Market Segments?

The omics-based clinical trials market covered in this report is segmented –

1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics

2) By Phase: Phase I, Phase II, Phase III, Phase IV

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders

5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories

Subsegments:

1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing

2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping

3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis

4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

Which Trends Are Influencing The Direction Of The Omics-Based Clinical Trials Market?

Leading entities within the omics lab services market are concentrating on crafting novel solutions, such as high-throughput genomics, to expedite biomedical research and the development of precision medicine. High-throughput genomics involves leveraging sophisticated technologies to swiftly sequence and analyze substantial quantities of DNA or RNA, thereby facilitating efficient large-scale genetic investigations. As an illustrative case, in September 2024, The Translational Genomics Research Institute (TGen), a US-based nonprofit medical research institution, established the Center for Spatial Multi-Omics (COSMO). This center delivers high-resolution whole-transcriptome data utilizing sequencing-based Visium HD alongside histological staining, and additionally provides tissue processing options like Tissue Microarray (TMA) construction for economical, multiplexed sample assessments. Its adaptable platforms, further improved by machine learning-driven cell segmentation, enable precise visualization and mapping of molecular information within preserved tissues, contributing to progress in precision medicine and disease understanding.

Who Are The Leading Firms Participating In The Omics-Based Clinical Trials Market?

Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.

Access The Complete Omics-Based Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

What Is The Largest Regional Market In The Omics-Based Clinical Trials Market?

North America was the largest region in the omics-based clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Omics-Based Clinical Trials Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp

Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2026, By The Business Research Company

Medical And Diagnostic Laboratory Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Medical And Diagnostic Laboratory Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Lab Supplies Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lab-supplies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Omics-Based Clinical Trials Market Progress Between 2026 And 2030?

The omics-based clinical trials market has shown robust expansion in recent years. Its valuation is expected to increase from $31.71 billion in 2025 to $34.49 billion in 2026, marking a compound annual growth rate (CAGR) of 8.8%. The growth observed historically can be attributed to several factors, including the rising complexity of clinical trial designs, the expansion of genomic and proteomic research, an escalating demand for personalized therapies, the enhancement of clinical research infrastructure, and increased collaborations between pharmaceutical companies and academic institutions.

The omics-based clinical trials market is anticipated to experience robust expansion over the coming years. This market is projected to reach a size of $47.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. The momentum behind this growth during the forecast period stems from the increasing integration of precision medicine techniques, a rise in investments directed at data-centric clinical trials, the broader deployment of AI for patient recruitment, the increasing regulatory endorsement of omics-based endpoints, and a heightened demand for streamlined trial outcomes. Significant trends expected during this period encompass the growing adoption of biomarker-driven trial structures, an increased application of multi-omics in patient stratification, the expanding integration of real-world evidence analytics, a proliferation of precision oncology clinical trials, and a strengthened emphasis on data-focused trial optimization.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp

What Key Factors Are Shaping The Omics-Based Clinical Trials Market Landscape?

The rising demand for personalized medicine is projected to fuel the expansion of the omics-based clinical trials market in the foreseeable future. Personalized medicine is defined as a medical approach that customizes disease prevention, diagnosis, and treatment to the unique characteristics of each patient. The need for personalized medicine is escalating due to advancements in genomic technologies, which facilitate faster and more cost-effective analysis of individual genetic profiles to guide specific treatments. Omics-based clinical trials support personalized medicine by enabling the identification of individual genetic, proteomic, and metabolic profiles, thereby allowing for more targeted and effective treatment strategies tailored to each patient. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022, with the 2023 approvals also encompassing seven oncology therapies and three treatments targeting various other conditions. Thus, the increasing demand for personalized medicine is driving the growth of the omics-based clinical trials market.

How Is The Omics-Based Clinical Trials Market Segmented Across Different Segment Categories?

The omics-based clinical trials market covered in this report is segmented –

1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics

2) By Phase: Phase I, Phase II, Phase III, Phase IV

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders

5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories

Subsegments:

1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing

2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping

3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis

4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

What Market Trends Are Affecting The Omics-Based Clinical Trials Market?

Leading companies active in the omics-based clinical trials market are prioritizing inventive solutions, like HiFi sequencing technology, to boost the accuracy, speed, and depth of multi-omics data analysis, consequently improving trial outcomes and personalized treatment strategies. HiFi sequencing is characterized as a next-generation sequencing (NGS) technology that yields long, highly precise reads via circular consensus sequencing (CCS), enabling comprehensive and exact analysis of genomes, transcriptomes, and epigenomes. For example, in October 2024, Pacific Biosciences of California Inc., a US-based biotechnology company, in collaboration with the Agency for Science, Technology, and Research (A*STAR), a Singapore-based research and product development agency, and Macrogen Inc., a South Korea-based biotechnology company, launched a cutting-edge laboratory to accelerate genomics innovation in Singapore utilizing advanced long-read sequencing technology. This facility allows researchers to conduct sophisticated genomic studies with greater accuracy and pace. It supports a wide array of applications, including whole genome sequencing, transcriptomics, epigenetics, and metagenomics. The lab additionally promotes collaboration among global scientists and local institutions, aiming to expedite discoveries in personalized medicine, rare disease diagnostics, and precision oncology. Moreover, it offers training programs and shared access to high-throughput sequencing infrastructure, thereby fostering capacity-building and innovation across the Asia-Pacific region.

Which Organizations Play A Role In The Omics-Based Clinical Trials Market Landscape?

Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.

Get The Full Omics-Based Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

Where Is The Omics-Based Clinical Trials Market Primarily Concentrated By Region?

North America was the largest region in the omics-based clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Omics-Based Clinical Trials Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2026, By The Business Research Company

Medical And Diagnostic Laboratory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Medical And Diagnostic Laboratory Services Market Report

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Lab Supplies Market Report

https://www.thebusinessresearchcompany.com/report/lab-supplies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Omics-Based Clinical Trials Market In 2026 And What Value Is Projected For 2030?

The omics-based clinical trials market has experienced strong expansion in recent years. It is anticipated to grow from $31.71 billion in 2025 to $34.49 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. This historical growth can be linked to several contributing factors, including the increasing complexity of clinical trial designs, advancements in genomic and proteomic research, a rising demand for personalized therapies, the expansion of clinical research infrastructure, and growing collaboration between pharmaceutical firms and academic institutions.

The omics-based clinical trials market size is projected to experience robust expansion over the forthcoming years. This market is anticipated to reach $47.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast period stems from several factors, including the increasing integration of precision medicine approaches, growing investments in data-driven clinical trials, the expanding use of AI-enabled patient recruitment, greater regulatory acceptance of omics-based endpoints, and a heightened demand for efficient trial outcomes. Key developments expected within the forecast period encompass a greater embrace of biomarker-driven trial designs, an increased application of multi-omics patient stratification, the deepening integration of real-world evidence analytics, the enlargement of precision oncology clinical trials, and an intensified focus on data-centric trial optimization.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp

What Key Drivers Are Influencing The Growth Of The Omics-Based Clinical Trials Market?

The expanding requirement for personalized medicine is projected to fuel the expansion of the omics-based clinical trials market in the future. This medical approach involves customizing disease prevention, diagnosis, and treatment based on the unique attributes of each patient. The heightened demand for personalized medicine stems from advancements in genomic technologies, which facilitate quicker and more economical analysis of individual genetic profiles to inform specific therapies. Omics-based clinical trials bolster personalized medicine through their capacity to identify distinct genetic, proteomic, and metabolic profiles, leading to more precise and efficacious treatment plans customized for individual patients. For example, data from February 2024, provided by the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, indicated that the US Food and Drug Administration sanctioned 16 novel personalized treatments for rare disease patients in 2023. This marked an increase from six approvals in 2022, with the 2023 clearances also covering seven oncology therapies and three treatments for diverse other conditions. Consequently, the escalating need for personalized medicine is serving as a primary impetus for the expansion of the omics-based clinical trials market.

What Are The Key Segments Of The Omics-Based Clinical Trials Market?

The omics-based clinical trials market covered in this report is segmented –

1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics

2) By Phase: Phase I, Phase II, Phase III, Phase IV

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders

5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories

Subsegments:

1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing

2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping

3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis

4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

How Are Trends Impacting The Omics-Based Clinical Trials Market?

Companies involved in the omics-based clinical trials market are prioritizing advanced solutions, like HiFi sequencing technology, to boost the precision, pace, and thoroughness of multi-omics data analysis, thereby enhancing trial results and individualized treatment approaches. HiFi sequencing is a next-generation sequencing (NGS) method that generates extended, highly accurate reads through circular consensus sequencing (CCS), enabling comprehensive and exact examinations of genomes, transcriptomes, and epigenomes. An illustrative example occurred in October 2024, when Pacific Biosciences of California Inc., a US-based biotechnology company, together with the Agency for Science, Technology, and Research (A*STAR), a Singapore-based research and product development agency, and Macrogen Inc., a South Korea-based biotechnology company, established a cutting-edge lab to propel genomics innovation in Singapore utilizing advanced long-read sequencing technology. This facility empowers researchers to carry out sophisticated genomic studies with improved accuracy and speed. It supports a broad array of applications, including whole genome sequencing, transcriptomics, epigenetics, and metagenomics. Furthermore, the lab encourages cooperation among international scientists and local institutions, aiming to accelerate breakthroughs in personalized medicine, rare disease diagnostics, and precision oncology. Additionally, it provides training courses and communal access to high-throughput sequencing infrastructure, fostering capacity development and innovation across the Asia-Pacific region.

Who Are The Leading Companies Operating In The Omics-Based Clinical Trials Market?

Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.

Read the full omics-based clinical trials market report here:

https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Omics-Based Clinical Trials Market?

North America was the largest region in the omics-based clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Omics-Based Clinical Trials Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp

Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2026, By The Business Research Company

Medical And Diagnostic Laboratory Services Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Medical And Diagnostic Laboratory Services Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Lab Supplies Global Market Report

https://www.thebusinessresearchcompany.com/report/lab-supplies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Omics-Based Clinical Trials Market In 2026 And What Value Is Projected For 2030?

The omics-based clinical trials market has experienced strong expansion in recent years. It is anticipated to grow from $31.71 billion in 2025 to $34.49 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. This historical growth can be linked to several contributing factors, including the increasing complexity of clinical trial designs, advancements in genomic and proteomic research, a rising demand for personalized therapies, the expansion of clinical research infrastructure, and growing collaboration between pharmaceutical firms and academic institutions.

The omics-based clinical trials market size is projected to experience robust expansion over the forthcoming years. This market is anticipated to reach $47.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast period stems from several factors, including the increasing integration of precision medicine approaches, growing investments in data-driven clinical trials, the expanding use of AI-enabled patient recruitment, greater regulatory acceptance of omics-based endpoints, and a heightened demand for efficient trial outcomes. Key developments expected within the forecast period encompass a greater embrace of biomarker-driven trial designs, an increased application of multi-omics patient stratification, the deepening integration of real-world evidence analytics, the enlargement of precision oncology clinical trials, and an intensified focus on data-centric trial optimization.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp

What Key Drivers Are Influencing The Growth Of The Omics-Based Clinical Trials Market?

The expanding requirement for personalized medicine is projected to fuel the expansion of the omics-based clinical trials market in the future. This medical approach involves customizing disease prevention, diagnosis, and treatment based on the unique attributes of each patient. The heightened demand for personalized medicine stems from advancements in genomic technologies, which facilitate quicker and more economical analysis of individual genetic profiles to inform specific therapies. Omics-based clinical trials bolster personalized medicine through their capacity to identify distinct genetic, proteomic, and metabolic profiles, leading to more precise and efficacious treatment plans customized for individual patients. For example, data from February 2024, provided by the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, indicated that the US Food and Drug Administration sanctioned 16 novel personalized treatments for rare disease patients in 2023. This marked an increase from six approvals in 2022, with the 2023 clearances also covering seven oncology therapies and three treatments for diverse other conditions. Consequently, the escalating need for personalized medicine is serving as a primary impetus for the expansion of the omics-based clinical trials market.

What Are The Key Segments Of The Omics-Based Clinical Trials Market?

The omics-based clinical trials market covered in this report is segmented –

1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics

2) By Phase: Phase I, Phase II, Phase III, Phase IV

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders

5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories

Subsegments:

1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing

2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping

3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis

4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

How Are Trends Impacting The Omics-Based Clinical Trials Market?

Companies involved in the omics-based clinical trials market are prioritizing advanced solutions, like HiFi sequencing technology, to boost the precision, pace, and thoroughness of multi-omics data analysis, thereby enhancing trial results and individualized treatment approaches. HiFi sequencing is a next-generation sequencing (NGS) method that generates extended, highly accurate reads through circular consensus sequencing (CCS), enabling comprehensive and exact examinations of genomes, transcriptomes, and epigenomes. An illustrative example occurred in October 2024, when Pacific Biosciences of California Inc., a US-based biotechnology company, together with the Agency for Science, Technology, and Research (A*STAR), a Singapore-based research and product development agency, and Macrogen Inc., a South Korea-based biotechnology company, established a cutting-edge lab to propel genomics innovation in Singapore utilizing advanced long-read sequencing technology. This facility empowers researchers to carry out sophisticated genomic studies with improved accuracy and speed. It supports a broad array of applications, including whole genome sequencing, transcriptomics, epigenetics, and metagenomics. Furthermore, the lab encourages cooperation among international scientists and local institutions, aiming to accelerate breakthroughs in personalized medicine, rare disease diagnostics, and precision oncology. Additionally, it provides training courses and communal access to high-throughput sequencing infrastructure, fostering capacity development and innovation across the Asia-Pacific region.

Who Are The Leading Companies Operating In The Omics-Based Clinical Trials Market?

Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.

Read the full omics-based clinical trials market report here:

https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Omics-Based Clinical Trials Market?

North America was the largest region in the omics-based clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Omics-Based Clinical Trials Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp

Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2026, By The Business Research Company

Medical And Diagnostic Laboratory Services Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Medical And Diagnostic Laboratory Services Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Lab Supplies Global Market Report

https://www.thebusinessresearchcompany.com/report/lab-supplies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Omics-Based Clinical Trials Market In 2026 And What Value Is Projected For 2030?

The omics-based clinical trials market has experienced strong expansion in recent years. It is anticipated to grow from $31.71 billion in 2025 to $34.49 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. This historical growth can be linked to several contributing factors, including the increasing complexity of clinical trial designs, advancements in genomic and proteomic research, a rising demand for personalized therapies, the expansion of clinical research infrastructure, and growing collaboration between pharmaceutical firms and academic institutions.

The omics-based clinical trials market size is projected to experience robust expansion over the forthcoming years. This market is anticipated to reach $47.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast period stems from several factors, including the increasing integration of precision medicine approaches, growing investments in data-driven clinical trials, the expanding use of AI-enabled patient recruitment, greater regulatory acceptance of omics-based endpoints, and a heightened demand for efficient trial outcomes. Key developments expected within the forecast period encompass a greater embrace of biomarker-driven trial designs, an increased application of multi-omics patient stratification, the deepening integration of real-world evidence analytics, the enlargement of precision oncology clinical trials, and an intensified focus on data-centric trial optimization.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp

What Key Drivers Are Influencing The Growth Of The Omics-Based Clinical Trials Market?

The expanding requirement for personalized medicine is projected to fuel the expansion of the omics-based clinical trials market in the future. This medical approach involves customizing disease prevention, diagnosis, and treatment based on the unique attributes of each patient. The heightened demand for personalized medicine stems from advancements in genomic technologies, which facilitate quicker and more economical analysis of individual genetic profiles to inform specific therapies. Omics-based clinical trials bolster personalized medicine through their capacity to identify distinct genetic, proteomic, and metabolic profiles, leading to more precise and efficacious treatment plans customized for individual patients. For example, data from February 2024, provided by the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, indicated that the US Food and Drug Administration sanctioned 16 novel personalized treatments for rare disease patients in 2023. This marked an increase from six approvals in 2022, with the 2023 clearances also covering seven oncology therapies and three treatments for diverse other conditions. Consequently, the escalating need for personalized medicine is serving as a primary impetus for the expansion of the omics-based clinical trials market.

What Are The Key Segments Of The Omics-Based Clinical Trials Market?

The omics-based clinical trials market covered in this report is segmented –

1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics

2) By Phase: Phase I, Phase II, Phase III, Phase IV

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders

5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories

Subsegments:

1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing

2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping

3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis

4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

How Are Trends Impacting The Omics-Based Clinical Trials Market?

Companies involved in the omics-based clinical trials market are prioritizing advanced solutions, like HiFi sequencing technology, to boost the precision, pace, and thoroughness of multi-omics data analysis, thereby enhancing trial results and individualized treatment approaches. HiFi sequencing is a next-generation sequencing (NGS) method that generates extended, highly accurate reads through circular consensus sequencing (CCS), enabling comprehensive and exact examinations of genomes, transcriptomes, and epigenomes. An illustrative example occurred in October 2024, when Pacific Biosciences of California Inc., a US-based biotechnology company, together with the Agency for Science, Technology, and Research (A*STAR), a Singapore-based research and product development agency, and Macrogen Inc., a South Korea-based biotechnology company, established a cutting-edge lab to propel genomics innovation in Singapore utilizing advanced long-read sequencing technology. This facility empowers researchers to carry out sophisticated genomic studies with improved accuracy and speed. It supports a broad array of applications, including whole genome sequencing, transcriptomics, epigenetics, and metagenomics. Furthermore, the lab encourages cooperation among international scientists and local institutions, aiming to accelerate breakthroughs in personalized medicine, rare disease diagnostics, and precision oncology. Additionally, it provides training courses and communal access to high-throughput sequencing infrastructure, fostering capacity development and innovation across the Asia-Pacific region.

Who Are The Leading Companies Operating In The Omics-Based Clinical Trials Market?

Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.

Read the full omics-based clinical trials market report here:

https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Omics-Based Clinical Trials Market?

North America was the largest region in the omics-based clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Omics-Based Clinical Trials Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp

Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2026, By The Business Research Company

Medical And Diagnostic Laboratory Services Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Medical And Diagnostic Laboratory Services Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Lab Supplies Global Market Report

https://www.thebusinessresearchcompany.com/report/lab-supplies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the omics-based clinical trials market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Omics-Based Clinical Trials Market by the end of 2030?

The omics-based clinical trials market has experienced significant expansion in recent years. Forecasts indicate it will advance from $31.71 billion in 2025 to $34.49 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. This historical growth is attributable to several key factors, including the increasing complexity of clinical trial designs, progress in genomic and proteomic research, a heightened demand for personalized therapies, the enlargement of clinical research infrastructure, and enhanced collaboration between pharmaceutical and academic institutions.

The market for omics-based clinical trials is projected to experience robust expansion over the coming years. This market is anticipated to reach $47.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This projected growth is driven by factors such as the increasing embrace of precision medicine, greater investments in clinical trials relying on data, the broader application of AI in patient recruitment, a rise in regulatory approval for omics-based endpoints, and a heightened need for effective trial results. Key developments expected during this forecast period encompass a greater prevalence of trial designs guided by biomarkers, expanded utilization of multi-omics for patient stratification, enhanced incorporation of real-world evidence analytics, an increase in precision oncology clinical trials, and a stronger emphasis on optimizing trials through data.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp

What Drivers Are Shaping Future Opportunities In The Omics-Based Clinical Trials Market?

The anticipated expansion of the omics-based clinical trials market is driven by the growing need for personalized medicine. This medical strategy customizes disease prevention, diagnosis, and treatment according to each patient’s unique characteristics. The increasing adoption of personalized medicine stems from progress in genomic technologies, which facilitate quicker and more economical analysis of individual genetic profiles to inform specific therapies. Omics-based clinical trials contribute to personalized medicine by enabling the identification of unique genetic, proteomic, and metabolic profiles, thus leading to more precise and efficacious treatment plans customized for each patient. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, reported that the US Food and Drug Administration sanctioned 16 novel personalized treatments for rare disease patients in 2023. This marks an increase from six approvals in 2022, with the 2023 approvals additionally covering seven oncology therapies and three treatments for various other ailments. Consequently, the expanding need for personalized medicine is fueling the growth of the omics-based clinical trials market.

Which Segment Groups Are Influencing The Omics-Based Clinical Trials Market?

The omics-based clinical trials market covered in this report is segmented –

1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics

2) By Phase: Phase I, Phase II, Phase III, Phase IV

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders

5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories

Subsegments:

1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing

2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping

3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis

4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

Which Innovation Trends Are Advancing Developments Within The Omics-Based Clinical Trials Market?

Leading companies in the omics-based clinical trials market are prioritizing innovative solutions, such as HiFi sequencing technology, to improve the accuracy, speed, and depth of multi-omics data analysis, ultimately enhancing trial outcomes and personalized treatment strategies. HiFi sequencing is a next-generation sequencing (NGS) technology that produces long, highly accurate reads through circular consensus sequencing (CCS), facilitating comprehensive and precise analysis of genomes, transcriptomes, and epigenomes. For instance, in October 2024, Pacific Biosciences of California Inc., a US-based biotechnology company, collaborated with the Agency for Science, Technology, and Research (A*STAR), a Singapore-based research and product development agency, and Macrogen Inc., a South Korea-based biotechnology company, to establish a state-of-the-art lab aimed at accelerating genomics innovation in Singapore using cutting-edge long-read sequencing technology. This facility allows researchers to perform advanced genomic studies with enhanced precision and speed. It supports a broad spectrum of applications, including whole genome sequencing, transcriptomics, epigenetics, and metagenomics. The lab also encourages collaboration among global scientists and local institutions, intending to accelerate discoveries in personalized medicine, rare disease diagnostics, and precision oncology. Additionally, it provides training programs and shared access to high-throughput sequencing infrastructure, fostering capacity-building and innovation throughout the Asia-Pacific region.

Who Are The Core Companies Influencing Trends In The Omics-Based Clinical Trials Market?

Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Omics-Based Clinical Trials Market?

North America was the largest region in the omics-based clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Omics-Based Clinical Trials Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp

Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2026, By The Business Research Company

Polymer Coated Fabrics Market Report 2026

https://www.thebusinessresearchcompany.com/report/polymer-coated-fabrics-global-market-report

Asphalt Additives Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report

Asphalt Pavers Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model